BLOG

What Quality and Safety Standards Apply to Adipose Stem Cell Processing in Japan?

8 min read

Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.

Regenerative medicine, particularly treatments using adipose-derived stem cells, is a field of growing global interest. For patients considering treatment in Japan, understanding the quality and safety standards involved is a top priority. Japan has a robust regulatory framework to oversee these advanced therapies. This article explains how the quality and safety of autologous (your own) adipose-derived stem cells are managed at a Japanese cell processing facility (CPF), providing insight for those exploring treatment options.

In Japan, the quality and safety of adipose-derived stem cell therapy are governed by a strict legal framework and meticulous processing standards. The Act on the Safety of Regenerative Medicine ensures national oversight, while specialized Cell Processing Facilities (CPFs) handle cell culturing in highly controlled environments, performing rigorous tests for sterility, viability, and purity. This system is designed to provide a high level of safety for patients.

Understanding the Concerns of International Patients

When seeking medical care abroad, it’s natural to have questions about safety, quality, and regulatory oversight. You might be wondering:

  • How does Japan regulate advanced treatments like stem cell therapy?
  • What steps are taken to prevent contamination or errors during cell processing?
  • Are the cells tested for quality before they are administered?
  • What is the role of the clinic versus the laboratory?

This article addresses these key points by explaining the standards applied at a Japanese Cell Processing Facility (CPF) for adipose stem cell therapy.

Japan’s Regulatory Framework: The Act on the Safety of Regenerative Medicine

A key element of Japan’s approach is the “Act on the Safety of Regenerative Medicine” (ASRM), enforced by the Ministry of Health, Labour and Welfare (MHLW). This law establishes a clear set of rules for providing regenerative therapies. Before a clinic like Grand Green Osaka Umekita Clinic can offer a treatment such as adipose-derived stem cell therapy, it must submit a detailed treatment plan to a certified committee and the MHLW for review and approval.

This plan outlines every aspect of the procedure, from how the cells are collected and processed to how they are administered and how patient safety is monitored. The law mandates that cell processing must be conducted in a facility that has received a specific license. This legal oversight ensures a baseline of safety and quality management across the country, offering a degree of reassurance to both domestic and international patients.

The Crucial Role of the Cell Processing Facility (CPF)

The process of preparing adipose-derived stem cells for therapy is not performed in the clinic itself. Instead, after a small amount of fat tissue is collected from the patient under local anesthesia, it is transported to a specialized, licensed Cell Processing Facility (CPF). A CPF is a highly controlled laboratory environment designed specifically for culturing and expanding human cells for therapeutic use.

These facilities operate under strict guidelines, often based on Good Manufacturing Practice (GMP) principles, which govern everything from air quality and equipment sterilization to personnel training and documentation. The separation of the clinical procedure (at the clinic) from the cell culture process (at the CPF) is a fundamental safety measure. It minimizes the risk of contamination and ensures that the complex task of cell expansion is handled by specialists in a dedicated, controlled environment.

Key Quality and Safety Checks in Cell Processing

Inside the CPF, the patient’s stem cells undergo a series of rigorous quality control checks throughout the culture process. The goal is to produce a final cell product that is safe, pure, and potent. While specific protocols may vary, the core principles of quality control are standardized.

  • Sterility Testing: The cell culture is tested at multiple stages to ensure it is free from bacteria and fungi. A contaminated product could pose a significant risk to the patient, so sterility is a top priority.
  • Mycoplasma and Endotoxin Testing: In addition to general sterility, specific tests are run to detect mycoplasma (a type of bacteria that can be difficult to find) and endotoxins (toxic substances released by certain bacteria).
  • Cell Viability and Count: Before the cells are released for administration, their viability (the percentage of living cells) is measured, and the total number of cells is counted. This helps ensure that the patient receives the intended dose of healthy, functional cells.
  • Identity and Purity Confirmation: Tests are performed to confirm that the cultured cells are indeed mesenchymal stem cells and that they are from the correct patient. This prevents mix-ups and ensures the correct cell type is being administered.
  • Strict Environmental Control: The entire process takes place within cleanrooms where air pressure, temperature, and humidity are tightly controlled to prevent contamination. Research has shown that even trace residues from decontamination agents can affect cell growth, highlighting the importance of meticulous environmental management.

What to Confirm Before Considering Treatment

Adipose-derived stem cell therapy is a promising option for some individuals, but it’s important to approach it with a clear understanding. This treatment is provided as a private medical service and is not covered by Japanese public health insurance. The potential outcomes can vary depending on the individual’s condition, age, and other health factors. It is not presented as a guaranteed cure for any disease.

A thorough consultation with a physician is essential to determine if this therapy is a suitable option for you. During this consultation, the doctor will review your medical history, explain the procedure in detail, and discuss the potential benefits as well as the possible risks and side effects. They will also provide information on the expected number of treatments, the duration of the therapy, and the total costs involved. Making an informed decision based on a professional medical evaluation is the most important first step.

At Grand Green Osaka Umekita Clinic, we provide consultations for patients interested in regenerative medicine. For more information about our approach to adipose-derived stem cell therapy, including details on the process, fees, and potential risks, please review our detailed treatment page.

Learn more about Adipose-Derived Stem Cell Therapy

Summary: A Framework for Trust in Japanese Regenerative Medicine

The safety and quality of adipose stem cell processing in Japan are upheld by a combination of national legislation, specialized facilities, and stringent, multi-layered quality control protocols. The Act on the Safety of Regenerative Medicine provides a legal foundation, while dedicated Cell Processing Facilities ensure that cell culture is performed in a controlled, sterile environment. From sterility tests to cell viability checks, every step is designed to ensure the final product meets high safety standards.

If you are considering regenerative medicine in Japan, understanding this framework can provide confidence in the process. At Grand Green Osaka Umekita Clinic, located in the heart of Osaka, we offer adipose-derived stem cell therapy in compliance with these national standards. We invite you to contact us to schedule a consultation and discuss whether this treatment option may be appropriate for you based on a physician’s assessment.

Learn more about Adipose-Derived Stem Cell Therapy

References

Supervising Physician

Hidenori Shimada

Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic

Hidenori Shimada

Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.

* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.

Back to article list › Back to Adipose-Derived Stem Cell Therapy ›

Grand Green Osaka South Building, Gate Tower 5F 5-54 Ofuka-cho, Kita-ku, Osaka 530-0011, Japan

TEL: 06-7653-8493 FAX: 06-7635-8052

Contact